VICENTE
ESTRADA PÉREZ
Profesor titular de universidad
![Foto de VICENTE](/img/nophoto.png)
![Foto de Hospital Clínico San Carlos de Madrid](/img/noimage_org.png)
Hospital Clínico San Carlos de Madrid
Madrid, EspañaPublicaciones en colaboración con investigadores/as de Hospital Clínico San Carlos de Madrid (144)
2024
-
A specific natural killer cells phenotypic signature associated to long term elite control of HIV infection
Journal of Medical Virology, Vol. 96, Núm. 5
-
Acceptability of Long-Acting Injectable Antiretroviral Treatment for HIV Management: Perspectives of Patients and Physicians in Spain
AIDS Patient Care and STDs, Vol. 38, Núm. 7, pp. 305-314
-
Incidence of sexually transmitted infections and screening models among pre-exposure prophylaxis users
Enfermedades Infecciosas y Microbiologia Clinica
-
Monkeypox virus genomic accordion strategies
Nature Communications, Vol. 15, Núm. 1
-
Mpox, herpes, and enteroviruses: Differential diagnosis
Journal of Medical Virology
-
Pre-exposure prophylaxis program in the Community of Madrid: Two years of experience
Enfermedades Infecciosas y Microbiologia Clinica
-
T Cell Homeostasis Disturbances in a Cohort of Long-Term Elite Controllers of HIV Infection
International Journal of Molecular Sciences, Vol. 25, Núm. 11
2023
-
Clinical outcomes by supplemental oxygen use in remdesivir-treated, hospitalised adults with COVID-19
Infectious Diseases Now, Vol. 53, Núm. 7
-
Differences in the inflammatory response among hospitalized patients with distinct variants of SARS-CoV-2
Frontiers in Immunology, Vol. 14
-
Monitoring monkeypox virus in saliva and air samples in Spain: a cross-sectional study
The Lancet Microbe, Vol. 4, Núm. 1, pp. e21-e28
-
Mortality reduction in older COVID-19-patients hospitalized in Spain during the second pandemic wave from the SEMI-COVID-19 Registry
Scientific Reports, Vol. 13, Núm. 1
-
Plitidepsin in adult patients with COVID-19 requiring hospital admission: A long-term follow-up analysis
Frontiers in Cellular and Infection Microbiology, Vol. 13
-
Specific Cellular and Humoral Immune Responses to the Neoantigen RBD of SARS-CoV-2 in Patients with Primary and Secondary Immunodeficiency and Healthy Donors
Biomedicines, Vol. 11, Núm. 4
-
Switching to bictegravir/emtricitabine/tenofovir alafenamide (BIC/FTC/TAF) plus darunavir/cobicistat in heavily antiretroviral-experienced, virologically suppressed HIV-infected adults receiving complex regimens
The Journal of antimicrobial chemotherapy, Vol. 78, Núm. 11, pp. 2696-2701
-
TRPC6 inhibitor (BI 764198) to reduce risk and severity of ARDS due to COVID-19: a phase II randomised controlled trial
Thorax, Vol. 78, Núm. 8, pp. 816-824
-
Tenofovir Disoproxil Fumarate/Emtricitabine and Baricitinib for Patients at High Risk of Severe Coronavirus Disease 2019: The PANCOVID Randomized Clinical Trial
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, Vol. 76, Núm. 3, pp. e116-e125
-
Use of Monoclonal Antibodies in Immunocompromised Patients Hospitalized with Severe COVID-19: A Retrospective Multicenter Cohort
Journal of Clinical Medicine, Vol. 12, Núm. 3
2022
-
Chronic Oral Anticoagulation Therapy and Prognosis of Patients Admitted to Hospital for COVID-19: Insights from the HOPE COVID-19 Registry
International Journal of Clinical Practice, Vol. 2022
-
Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Versus Dolutegravir/Abacavir/Lamivudine in Antiretroviral-Naive Adults (SYMTRI): A Multicenter Randomized Open-Label Study (PReEC/RIS-57)
Open Forum Infectious Diseases
-
Discovering HIV related information by means of association rules and machine learning
Scientific Reports, Vol. 12, Núm. 1